☆ 4.7 Review

Radiation and Immune Checkpoint Inhibitors: Combination Therapy for Treatment of Hepatocellular Carcinoma

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Biochemistry & Molecular Biology

FDA-Approved Monoclonal Antibodies for Unresectable Hepatocellular Carcinoma: What Do We Know So Far?

Iason Psilopatis et al.

Summary: Unresectable hepatocellular carcinoma (HCC) is a poor-prognosis advanced primary liver malignancy. The FDA has approved several monoclonal antibodies (mAbs) including nivolumab, pembrolizumab, ramucirumab, nivolumab/ipilimumab, atezolizumab/bevacizumab, and tremelimumab/durvalumab as first- or second-line therapies for unresectable HCC. This review provides an update on the safety and efficacy of these mAbs, aiming to determine their suitability for different patient subgroups.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

添加到收藏夹

Review Immunology

Radiation therapy in the era of immune treatment for hepatocellular carcinoma

Lingjuan Chen et al.

Summary: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment and offer new opportunities for hepatocellular carcinoma (HCC) treatment. ICIs have high response rates, but HCC can evade immune system and limit their efficacy. Radiation therapy (RT) is gaining attention as a combination partner with ICIs due to its ability to modulate the tumor microenvironment. This review aims to provide references for future research on a promising new era of HCC treatment through the combination of ICIs and RT.

FRONTIERS IN IMMUNOLOGY (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Ipilimumab with atezolizumab-bevacizumab in patients with advanced hepatocellular carcinoma: The PRODIGE 81-FFCD 2101-TRIPLET-HCC trial

Philippe Merle et al.

Summary: The current first line systemic therapies for hepatocellular carcinoma are atezolizumab/bevacizumab and durvalumab/tremelimumab. However, the median overall survival is still below 20 months, and only a minority of patients become long-term survivors. The TRIPLET-HCC trial aims to evaluate the efficacy and safety of a triple combination therapy by adding ipilimumab to atezolizumab/bevacizumab compared to a double combination therapy.

DIGESTIVE AND LIVER DISEASE (2023)

添加到收藏夹

Article Oncology

Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma

Aditya Juloori et al.

Summary: This study investigated the safety and efficacy of stereotactic body radiation therapy (SBRT) with immunotherapy in patients with hepatocellular carcinoma (HCC). The results showed that the combination of SBRT with nivolumab plus ipilimumab had better survival and efficacy compared to immunotherapy alone in HCC patients, suggesting the need for further investigation.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2023)

添加到收藏夹

Article Oncology

Anlotinib Combined With Toripalimab as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Prospective, Multicenter, Phase II Study

Cheng-Sheng Zhang et al.

Summary: This study evaluates the efficacy and safety of anlotinib combined with toripalimab as first-line therapy for unresectable hepatocellular carcinoma. The results demonstrate that this combination therapy offers promising efficacy and manageable safety in Chinese patients with unresectable hepatocellular carcinoma.

ONCOLOGIST (2023)

添加到收藏夹

Article Oncology

Toripalimab in combination with Anlotinib for unresectable hepatocellular carcinoma after SBRT: A prospective, single-arm, single-center clinical study

Yongbiao Chen et al.

Summary: The study aimed to investigate the clinical efficacy and safety of SBRT combined with Toripalimab and Anlotinib for uHCC. The results showed that exposing specific antigens of HCC via SBRT may improve the efficacy of combinational therapy with Toripalimab and Anlotinib, with manageable adverse effects.

FRONTIERS IN ONCOLOGY (2023)

添加到收藏夹

Review Pharmacology & Pharmacy

Tremelimumab: First Approval

Susan J. J. Keam

Summary: Tremelimumab, a CTLA-4 blocking antibody, has been approved for the treatment of unresectable hepatocellular carcinoma and metastatic non-small cell lung cancer in the USA. It has also received a positive opinion for the first-line treatment of advanced or unresectable HCC from the EU Committee for Medicinal Products for Human Use. The drug is currently under regulatory review in Japan and other countries worldwide.

DRUGS (2023)

添加到收藏夹

Article Oncology

Radiation Therapy With Combination Therapy of Immune Checkpoint Inhibitors and Antiangiogenic Therapy for Hepatocellular Carcinoma

Cong Ning et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2023)

添加到收藏夹

Article Oncology

Stereotactic Body Radiotherapy for Hepatocellular Carcinoma: A Brief Overview

Yukinori Matsuo

Summary: Stereotactic body radiotherapy (SBRT) is an effective alternative therapy for hepatocellular carcinoma (HCC) when standard treatments are not suitable. It has the potential to improve prognosis of HCC by achieving high local control rates. However, further research is needed to determine optimal use of SBRT in combination with other treatments and the evaluation of post-SBRT imaging.

CURRENT ONCOLOGY (2023)

添加到收藏夹

Article Oncology

Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial

Thomas Yau et al.

Summary: First-line nivolumab treatment did not significantly improve overall survival compared with sorafenib in patients with advanced hepatocellular carcinoma, but clinical activity and a favorable safety profile were observed in some patients.

LANCET ONCOLOGY (2022)

添加到收藏夹

Review Oncology

Immunotherapies for hepatocellular carcinoma

Josep M. Llovet et al.

Summary: Liver cancer, specifically hepatocellular carcinoma (HCC), is the second leading cause of cancer-related death globally. Traditional treatments involve specific drugs, but the emergence of immune checkpoint inhibitors has revolutionized the management of HCC.

NATURE REVIEWS CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

External Beam Radiation Therapy for Primary Liver Cancers: An ASTRO Clinical Practice Guideline

Smith Apisarnthanarax et al.

Summary: This guideline provides evidence-based recommendations for external beam radiation therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma, covering indications, techniques, outcomes, and emphasizing multidisciplinary care. Future studies should focus on defining the role of EBRT in the context of liver directed and systemic therapies.

PRACTICAL RADIATION ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Mathematical Modeling to Simulate the Effect of Adding Radiation Therapy to Immunotherapy and Application to Hepatocellular Carcinoma

Wonmo Sung et al.

Summary: This study develops a comprehensive framework to simulate the response of immune checkpoint inhibitors (ICIs) in combination with radiation therapy (RT) in patients with hepatocellular carcinoma (HCC). The framework successfully describes tumor volume trajectories observed in early-stage clinical trials and predicts the efficacy of combination treatments. It provides guidance for clinical trial design.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2022)

添加到收藏夹

Article Oncology

Outcomes and Toxicities of Modern Combined Modality Therapy with Atezolizumab Plus Bevacizumab and Radiation Therapy for Hepatocellular Carcinoma

Gohar Shahwar Manzar et al.

Summary: This study reports the first experience of combined radiation therapy and modern systemic therapy for hepatocellular carcinoma (HCC). The combination therapy is safe and well-tolerated, with a faster recovery of absolute lymphocyte counts (ALCs) compared to other treatment regimens, which may serve as a favorable prognosticator.

CANCERS (2022)

添加到收藏夹

Article Oncology

NRG/RTOG 1112: Randomized Phase III Study of Sorafenib vs. Stereotactic Body Radiation Therapy (SBRT) Followed by Sorafenib in Hepatocellular Carcinoma (HCC) (NCT01730937)

L.A. Dawson et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2022)

添加到收藏夹

Review Oncology

Hepatocellular Carcinoma Intrinsic Cell Death Regulates Immune Response and Prognosis

Valli De Re et al.

Summary: Ablative and locoregional treatment options are effective therapies for early-stage HCC, enhancing immunogenicity and survival rates. Surgical approaches combined with immune-modulating drugs show promise in maximizing therapeutic outcomes.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹

Meeting Abstract Oncology

Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A randomized, phase III trial

S. Qin et al.

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Combining stereotactic body radiotherapy with camrelizumab for unresectable hepatocellular carcinoma: a single-arm trial

Jian-Xu Li et al.

Summary: This study evaluated the efficacy and safety of combining palliative SBRT with camrelizumab in patients with unresectable hepatocellular carcinoma (uHCC). The results showed promising antitumor activity against uHCC with manageable toxicities.

HEPATOLOGY INTERNATIONAL (2022)

添加到收藏夹

Article Immunology

PD-1 inhibitors plus anti-angiogenic therapy with or without intensity-modulated radiotherapy for advanced hepatocellular carcinoma: A propensity score matching study

Ke Su et al.

Summary: This study demonstrates the promising efficacy of the combination of PD-1 inhibitors with anti-angiogenic therapy and IMRT for HCC. The combination therapy group showed higher objective response rate, longer median overall survival, and median progression-free survival compared to the control group.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Article Oncology

Ablative radiation therapy for hepatocellular carcinoma is associated with reduced treatment- and tumor-related liver failure and improved survival

Lara Hilal et al.

Summary: The study retrospectively analyzed outcomes of HCC patients treated with liver radiation therapy, finding that ablative RT can achieve over 90% local control in inoperable patients while minimizing tumor-and treatment-related liver failure, leading to improved survival.

JOURNAL OF GASTROINTESTINAL ONCOLOGY (2021)

添加到收藏夹

Review Oncology

Systemic therapy of advanced hepatocellular carcinoma

Peter R Galle et al.

Summary: For a decade, sorafenib was the main treatment for advanced hepatocellular carcinoma, but recent approvals of new systemic treatments, including immunotherapies, have shifted the landscape. The combination of a checkpoint inhibitor with a VEGF antibody has shown promising results, raising questions about treatment choices and sequences.

FUTURE ONCOLOGY (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination

Jiali Yu et al.

Summary: Liver metastases diminish the efficacy of immunotherapy by siphoning activated CD8(+) T cells from systemic circulation, creating systemic immune desert. Combining liver-directed radiotherapy with immunotherapy can promote systemic antitumor immunity.

NATURE MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Hepatocellular carcinoma

Josep M. Llovet et al.

Summary: Liver cancer, particularly hepatocellular carcinoma (HCC), poses a significant global health challenge with rising incidence projected to exceed 1 million cases by 2025. Infection by hepatitis B and C viruses remains a major risk factor for HCC, while non-alcoholic steatohepatitis is emerging as a more common risk factor in Western countries. Advances in systemic therapies for HCC, including immunotherapies and targeted therapies, are expected to revolutionize the management of this disease.

NATURE REVIEWS DISEASE PRIMERS (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Radiation-induced abscopal effect and its enhancement by programmed cell death 1 blockade in the hepatocellular carcinoma: A murine model study

Gyu Sang Yoo et al.

Summary: In a murine model of HCC, combining radiation therapy and immunotherapy enhanced the abscopal effect by inhibiting tumor growth and increasing infiltration of activated cytotoxic T cells.

CLINICAL AND MOLECULAR HEPATOLOGY (2021)

添加到收藏夹

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

添加到收藏夹

Article Oncology

Combined Stereotactic Body Radiotherapy and Immunotherapy Versus Transarterial Chemoembolization in Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis

Chi-Leung Chiang et al.

Summary: After translation, it is revealed that the combination of stereotactic SBRT-IO and TACE showed better survival and lower treatment toxicity in patients with locally advanced HCC.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Meeting Abstract Oncology

Results from a global phase 2 study of tislelizumab, an investigational PD-1 antibody, in patients with unresectable hepatocellular carcinoma

M. Ducreux et al.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Phase 2 Study of Adjuvant Radiotherapy Following Narrow-Margin Hepatectomy in Patients With HCC

Bo Chen et al.

Summary: This study investigated the efficacy and safety of postoperative intensity-modulated radiotherapy (IMRT) for HCC after narrow-margin hepatectomy. The results showed promising overall survival (OS) and disease-free survival (DFS) rates for patients, with intrahepatic recurrence being the primary pattern. Adjuvant radiotherapy was well-tolerated and demonstrated potential as an effective adjuvant regimen for HCC patients.

HEPATOLOGY (2021)

添加到收藏夹

Review Oncology

Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer

Hao Zhang et al.

Summary: The regulatory mechanisms of PD-L1 and CTLA-4 play a crucial role in immunotherapy, and understanding their interactions can help improve patients' treatment responses and clinical care.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Article Oncology

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study

Zhenggang Ren et al.

Summary: The study aimed to assess the efficacy of sintilimab plus IBI305 versus sorafenib as a first-line treatment for unresectable HBV-associated hepatocellular carcinoma in China, showing significant overall survival and progression-free survival benefits with acceptable safety profiles.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Combination of Sorafenib, Camrelizumab, Transcatheter Arterial Chemoembolization, and Stereotactic Body Radiation Therapy as a Novel Downstaging Strategy in Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Case Series Study

Yun Huang et al.

Summary: The study showed that combination therapy with sorafenib, camrelizumab, TACE, and SBRT is an effective downstaging strategy for advanced HCC with PVTT, resulting in good treatment responses and survival outcomes with few adverse events.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Hepatobiliary Cancers, Version 2.2021

Al B. Benson III et al.

Summary: The NCCN Guidelines for Hepatobiliary Cancers provide recommendations for screening, diagnosis, staging, treatment, and management of HCC, gallbladder cancer, and cancer of the bile ducts. A multidisciplinary evaluation is crucial for determining optimal treatment strategies, with significant advancements in systemic treatment of HCC beyond traditional options like sorafenib.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)

添加到收藏夹

Review Oncology

Efficacy and safety of radiotherapy for primary liver cancer

Wenqi Chen et al.

Summary: Primary liver cancer, including hepatocellular carcinoma and intrahepatic cholangiocarcinoma, is often not suitable for surgical treatment, but surgical resection, liver transplantation, and radiation therapy are effective options for early-stage cases. Radiation therapy, including techniques like 3DCRT, IMRT, SBRT, VMAT, and internal radiation therapies, is increasingly being used in potentially curative settings for treating advanced liver cancer.

CHINESE CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Hypofractionated Irradiation Suppressed the Off-Target Mouse Hepatocarcinoma Growth by Inhibiting Myeloid-Derived Suppressor Cell-Mediated Immune Suppression

Junying Chen et al.

FRONTIERS IN ONCOLOGY (2020)

添加到收藏夹

Letter Oncology

The effect of radiation therapy on the objective response and outcomes with nivolumab for hepatocellular carcinoma

William H. Smith et al.

ACTA ONCOLOGICA (2020)

添加到收藏夹

Article Medicine, Research & Experimental

Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma

Robin K. Kelley et al.

ADVANCES IN THERAPY (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Palliative Liver Radiotherapy (RT) for Symptomatic Hepatocellular Carcinoma (HCC)

Cynthia S. Y. Yeung et al.

SCIENTIFIC REPORTS (2020)

添加到收藏夹

Review Oncology

Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma

Masatoshi Kudo

CANCERS (2020)

添加到收藏夹

Article Medicine, General & Internal

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Review Immunology

Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond

Yun Hua Lee et al.

FRONTIERS IN IMMUNOLOGY (2020)

添加到收藏夹

Article Oncology

Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib The CheckMate 040 Randomized Clinical Trial

Thomas Yau et al.

JAMA ONCOLOGY (2020)

添加到收藏夹

Review Gastroenterology & Hepatology

Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Current State and Future Opportunities

Payal D. Soni et al.

DIGESTIVE DISEASES AND SCIENCES (2019)

添加到收藏夹

Article Oncology

Protons versus Photons for Unresectable Hepatocellular Carcinoma: Liver Decompensation and Overall Survival

Nina N. Sanford et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2019)

添加到收藏夹

Review Medicine, General & Internal

Hepatocellular Carcinoma

Augusto Villanueva

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Review Oncology

The Combination of Stereotactic Body Radiation Therapy and Immunotherapy in Primary Liver Tumors

Malek Kreidieh et al.

JOURNAL OF ONCOLOGY (2019)

添加到收藏夹

Meeting Abstract Oncology

The Safety of Nivolumab in Combination with Prior or Concurrent Radiation Therapy Among Patients with Hepatocellular Carcinoma

W. H. Smith et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2019)

添加到收藏夹

Review Gastroenterology & Hepatology

A global view of hepatocellular carcinoma: trends, risk, prevention and management

Ju Dong Yang et al.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2019)

添加到收藏夹

Review Gastroenterology & Hepatology

Locoregional treatments for hepatocellular carcinoma: Current evidence and future directions

Riccardo Inchingolo et al.

WORLD JOURNAL OF GASTROENTEROLOGY (2019)

添加到收藏夹

Article Oncology

Combined Stereotactic Body Radiotherapy and Checkpoint Inhibition in Unresectable Hepatocellular Carcinoma: A Potential Synergistic Treatment Strategy

Chi-Leung Chiang et al.

FRONTIERS IN ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Andrew X. Zhu et al.

LANCET ONCOLOGY (2019)

添加到收藏夹

Review Gastroenterology & Hepatology

Radiotherapy for HCC: Ready for prime time?

Andrew Bang et al.

JHEP REPORTS (2019)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Comparing photon and proton-based hypofractioned SBRT for prostate cancer accounting for robustness and realistic treatment deliverability

Lee C. Goddard et al.

BRITISH JOURNAL OF RADIOLOGY (2018)

添加到收藏夹

Article Oncology

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Andrew X. Zhu et al.

LANCET ONCOLOGY (2018)

添加到收藏夹

Review Oncology

Abscopal effect of radiotherapy combined with immune checkpoint inhibitors

Yang Liu et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)

添加到收藏夹

Review Gastroenterology & Hepatology

Proton therapy for hepatocellular carcinoma: Current knowledges and future perspectives

Gyu Sang Yoo et al.

WORLD JOURNAL OF GASTROENTEROLOGY (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

Programmed cell death-1 blockade enhances response to stereotactic radiation in an orthotopic murine model of hepatocellular carcinoma

David Friedman et al.

HEPATOLOGY RESEARCH (2017)

添加到收藏夹

Article Oncology

A comparative analysis between sequential boost and integrated boost intensity-modulated radiation therapy with concurrent chemotherapy for locally-advanced head and neck cancer

Gregory Vlacich et al.

RADIATION ONCOLOGY (2017)

添加到收藏夹

Review Oncology

Intensity-modulated radiotherapy for hepatocellular carcinoma: dosimetric and clinical results

Sun Hyun Bae et al.

ONCOTARGET (2017)

添加到收藏夹

Article Oncology

Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model

Kyoung-Jin Kim et al.

ONCOTARGET (2017)

添加到收藏夹

Review Biochemistry & Molecular Biology

Radiation-induced liver disease: current understanding and future perspectives

Jieun Kim et al.

EXPERIMENTAL AND MOLECULAR MEDICINE (2017)

添加到收藏夹

Review Oncology

CTLA-4 and PD-1 Pathways Similarities, Differences, and Implications of Their Inhibition

Elizabeth I. Buchbinder et al.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2016)

添加到收藏夹

Review Oncology

Solutions that enable ablative radiotherapy for large liver tumors: Fractionated dose painting, simultaneous integrated protection, motion management, and computed tomography image guidance

Christopher H. Crane et al.

CANCER (2016)

添加到收藏夹

Article Oncology

The clinical and prognostic significance of CD14+HLA-DR-/low myeloid-derived suppressor cells in hepatocellular carcinoma patients receiving radiotherapy

Dong Wang et al.

TUMOR BIOLOGY (2016)

添加到收藏夹

Article Multidisciplinary Sciences

Optimizing Timing of Immunotherapy Improves Control of Tumors by Hypofractionated Radiation Therapy

Kristina H. Young et al.

PLOS ONE (2016)

添加到收藏夹

Review Oncology

Application of radiotherapy for hepatocellular carcinoma in current clinical practice guidelines

Chai Hong Rim et al.

RADIATION ONCOLOGY JOURNAL (2016)

添加到收藏夹

Article Hematology

The Role of Consolidative Radiotherapy after a Complete Response to Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma in the Rituximab Era: Results from a Systematic Review with a Meta-Analysis

Chunhong Hu et al.

ACTA HAEMATOLOGICA (2015)

添加到收藏夹

Review Oncology

The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant

Kobe Reynders et al.

CANCER TREATMENT REVIEWS (2015)

添加到收藏夹

Article Oncology

The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment

Gregory K. Pennock et al.

ONCOLOGIST (2015)

添加到收藏夹

Article Multidisciplinary Sciences

Proton beam radiation induces DNA damage and cell apoptosis in glioma stem cells through reactive oxygen species

R. Alan Mitteer et al.

SCIENTIFIC REPORTS (2015)

添加到收藏夹

Review Gastroenterology & Hepatology

Immunology of hepatocellular carcinoma

Meenakshi Sachdeva et al.

WORLD JOURNAL OF HEPATOLOGY (2015)

添加到收藏夹

Review Gastroenterology & Hepatology

Role of radiotherapy in the management of hepatocellular carcinoma: A systematic review

Maria-Aggeliki Kalogeridi et al.

WORLD JOURNAL OF HEPATOLOGY (2015)

添加到收藏夹

Article Oncology

Stereotactic body radiotherapy for small hepatocellular carcinoma: A retrospective outcome analysis in 185 patients

Naoko Sanuki et al.

ACTA ONCOLOGICA (2014)

添加到收藏夹

Article Oncology

Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade

Simon J. Dovedi et al.

CANCER RESEARCH (2014)

添加到收藏夹

Article Immunology

STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors

Liufu Deng et al.

IMMUNITY (2014)

添加到收藏夹

Article Biology

Autophagy: Detection, regulation and its role in cancer and therapy response

Pia Hoenscheid et al.

INTERNATIONAL JOURNAL OF RADIATION BIOLOGY (2014)

添加到收藏夹

Article Oncology

Improved oncologic outcomes with image-guided intensity-modulated radiation therapy using helical tomotherapy in locally advanced hepatocellular carcinoma

Hong In Yoon et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2014)

添加到收藏夹

Article Oncology

Three-dimensional conformal radiotherapy for portal vein tumor thrombosis alone in advanced hepatocellular carcinoma

Ju Hye Lee et al.

RADIATION ONCOLOGY JOURNAL (2014)

添加到收藏夹

Article Gastroenterology & Hepatology

Epidemiology of Hepatocellular Carcinoma Consider the Population

Sahil Mittal et al.

JOURNAL OF CLINICAL GASTROENTEROLOGY (2013)

添加到收藏夹

Article Multidisciplinary Sciences

Three-Dimensional Conformal Radiotherapy for Hepatocellular Carcinoma in Patients Unfit for Resection, Ablation, or Chemotherapy: A Retrospective Study

Vassilis Kouloulias et al.

SCIENTIFIC WORLD JOURNAL (2013)

添加到收藏夹

Review Immunology

The innate immune response during liver inflammation and metabolic disease

Veerie Bieghs et al.

TRENDS IN IMMUNOLOGY (2013)

添加到收藏夹

Article Gastroenterology & Hepatology

Role of innate immunity in the development of hepatocellular carcinoma

Rajagopal N. Aravalli

WORLD JOURNAL OF GASTROENTEROLOGY (2013)

添加到收藏夹

Review Oncology

Proton therapy for hepatocellular carcinoma

Ted C. Ling et al.

CHINESE JOURNAL OF CANCER RESEARCH (2012)

添加到收藏夹

Article Immunology

Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2

Tadashi Yokosuka et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2012)

添加到收藏夹

Review Oncology

Immunogenic cell death and DAMPs in cancer therapy

Dmitri V. Krysko et al.

NATURE REVIEWS CANCER (2012)

添加到收藏夹

Article Oncology

The Efficacy of Radiotherapy Relies upon Induction of Type I Interferon-Dependent Innate and Adaptive Immunity

Byron C. Burnette et al.

CANCER RESEARCH (2011)

添加到收藏夹

Article Oncology

Hepatic Radiation Toxicity: Avoidance and Amelioration

Chandan Guha et al.

SEMINARS IN RADIATION ONCOLOGY (2011)

添加到收藏夹

Review Immunology

The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses

Lucy S. K. Walker et al.

NATURE REVIEWS IMMUNOLOGY (2011)

添加到收藏夹

Review Oncology

Charged particles in radiation oncology

Marco Durante et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2010)

添加到收藏夹

Article Oncology

RADIOTHERAPEUTIC PARAMETERS PREDICTIVE OF LIVER COMPLICATIONS INDUCED BY LIVER TUMOR RADIOTHERAPY

Ik Jae Lee et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2009)

添加到收藏夹

Article Surgery

Role of the width of the surgical margin in a hepatectomy for small hepatocellular carcinomas eligible for percutaneous local ablative therapy

Kazuaki Shimada et al.

AMERICAN JOURNAL OF SURGERY (2008)

添加到收藏夹

Article Gastroenterology & Hepatology

A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4+CD25+Foxp3+ T cells

Bastian Hoechst et al.

GASTROENTEROLOGY (2008)

添加到收藏夹

Article Gastroenterology & Hepatology

Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients

Junliang Fu et al.

GASTROENTEROLOGY (2007)

添加到收藏夹

Review Oncology

Intensity modulating and other radiation therapy devices for dose painting

James M. Galvin et al.

JOURNAL OF CLINICAL ONCOLOGY (2007)

添加到收藏夹

Article Surgery

Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma - A prospective randomized trial

Ming Shi et al.

ANNALS OF SURGERY (2007)

添加到收藏夹

Article Gastroenterology & Hepatology

The liver as an immunological organ

V Racanelli et al.

HEPATOLOGY (2006)

添加到收藏夹

Article Immunology

Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor

AA Lugade et al.

JOURNAL OF IMMUNOLOGY (2005)

添加到收藏夹

Article Oncology

Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey

I Ikai et al.

CANCER (2004)

添加到收藏夹

Review Oncology

Metabolic oxidation/reduction reactions and cellular responses to ionizing radiation: A unifying concept in stress response biology

DR Spitz et al.

CANCER AND METASTASIS REVIEWS (2004)

添加到收藏夹

Article Immunology

Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy

M Chakraborty et al.

JOURNAL OF IMMUNOLOGY (2003)

添加到收藏夹

Review Medicine, General & Internal

Inflammation and cancer: back to Virchow?

F Balkwill et al.

LANCET (2001)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.